以华明产阿霉素为主联合化疗9425例恶性肿瘤临床疗效综合分析

本文综合了全国26个省、自治区、直辖市内180家医院应用鮀滨-华明产阿霉素单剂或联合方案治疗42种癌症患者9425例的近期疗效和毒副反应资料,在可评价的8314例各类恶性肿瘤患者中,完全缓解者1502例,部分缓解者2928例,总有效率为53.3％。其中以恶性淋巴瘤的缓解率最高,达83.8％;小细胞肺癌次之,达73.9％。毒副反应以骨髓抑制、胃肠反应、脱发为多见。相当一部分资料将华明产品与进口同类产品进行了比较,结论为:疗效肯定,毒副反应与进口品相似,价格低廉,值得大力推广应用。

An Analysis of Clinical Response of Huaming's Doxorubicin Combination Therapy in Treating 9425 Cases with Malignant Diseases

Short term responses and untoward effects of Huaming's Doxorubicin either alone or in combination with other agents were evaluated in 9425 patients with 42 kinds of malignant tumors pooled from 180 hospitals in 26 provinces and autonomous regions including Guangdong,Guangxi and Beijing. Of these 8314 were evaluable,CR was seen in 1502 cases, and PR in 2928 cases. The response rate was 53.3%. The highest response rate was noted in malignant lymphomas being 83.8%,followed by SCLC,73.9%. Untoward effects were observed mainly as expressed by bone mar- row inhibition, gastrointestinal disturbance and alopecia. A comparative study has been made between Huaming's Doxoru- bicin and imported adriamyein in many of the studies. It is concluded that the responses and the untoward effects of Huaming's Doxorubicin were about the same as those of imported adriamycin but its price is much lower. Therefore it is suggested to widely enlarge the use of Huaming's Doxorubicin in patients with cancer.